Cargando…

An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More”

BACKGROUND: Considering that most men benefit diagnostically from increased sampling of index lesions, limiting systematic biopsy (SBx) to the region around the index lesion could potentially minimize overdetection while maintaining the detection of clinically significant prostate cancer (csPCa). OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagens, Marinus J., Noordzij, M. Arjen, Mazel, Jan Willem, Jager, Auke, Boellaard, Thierry N., Tielbeek, Jeroen A.W., Henebiens, Margot, Schoots, Ivo G., van Leeuwen, Pim J., van der Poel, Henk G., Rynja, Sybren P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638771/
https://www.ncbi.nlm.nih.gov/pubmed/36353069
http://dx.doi.org/10.1016/j.euros.2022.07.006
_version_ 1784825497452019712
author Hagens, Marinus J.
Noordzij, M. Arjen
Mazel, Jan Willem
Jager, Auke
Boellaard, Thierry N.
Tielbeek, Jeroen A.W.
Henebiens, Margot
Schoots, Ivo G.
van Leeuwen, Pim J.
van der Poel, Henk G.
Rynja, Sybren P.
author_facet Hagens, Marinus J.
Noordzij, M. Arjen
Mazel, Jan Willem
Jager, Auke
Boellaard, Thierry N.
Tielbeek, Jeroen A.W.
Henebiens, Margot
Schoots, Ivo G.
van Leeuwen, Pim J.
van der Poel, Henk G.
Rynja, Sybren P.
author_sort Hagens, Marinus J.
collection PubMed
description BACKGROUND: Considering that most men benefit diagnostically from increased sampling of index lesions, limiting systematic biopsy (SBx) to the region around the index lesion could potentially minimize overdetection while maintaining the detection of clinically significant prostate cancer (csPCa). OBJECTIVE: To evaluate the diagnostic performance of a hypothetical magnetic resonance imaging (MRI)-directed targeted-plus-perilesional biopsy approach. DESIGN, SETTING, AND PARTICIPANTS: This single-center, retrospective analysis of prospectively generated data included all biopsy-naïve men with unilateral MRI-positive lesions (Prostate Imaging Reporting and Data System category ≥3), undergoing both MRI-directed targeted biopsies and SBx. Grade group 2–5 cancers were considered csPCa. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The diagnostic performance of a targeted-plus-perilesional biopsy approach was compared with that of a targeted-plus-systematic biopsy approach. The primary outcome was the detection of csPCa. Secondary outcomes included the detection of clinically insignificant prostate cancer (ciPCa) and the number of total biopsy cores. RESULTS AND LIMITATIONS: A total of 235 men were included in the analysis; csPCa and ciPCa were detected, respectively, in 95 (40.4%) and 86 (36.6%) of these 235 men. A targeted-plus-perilesional biopsy approach would have detected 92/95 (96.8%; 95% confidence interval [CI] 91.0–99.3%) csPCa cases. At the same time, detection of systematically found ciPCa would be reduced by 11/86 (12.8%; 95% CI 6.6–21.7%). If a targeted-plus-perilesional biopsy approach would have been performed, the number of biopsy cores per patient would have been reduced significantly (a mean difference of 5.2; 95% CI 4.9–5.6, p < 0.001). CONCLUSIONS: An MRI-directed targeted-plus-perilesional biopsy approach detected almost all csPCa cases, while limiting overdiagnosis and reducing the number of biopsy cores. Prospective clinical trials are needed to substantiate the withholding of nonperilesional SBx in men with unilateral lesion(s) on MRI. PATIENT SUMMARY: Limiting systematic biopsies to the proximity of the suspicious area on magnetic resonance imaging helps detect an equivalent number of aggressive cancers and fewer indolent cancers. These findings may help patients and physicians choose the best biopsy approach.
format Online
Article
Text
id pubmed-9638771
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96387712022-11-08 An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More” Hagens, Marinus J. Noordzij, M. Arjen Mazel, Jan Willem Jager, Auke Boellaard, Thierry N. Tielbeek, Jeroen A.W. Henebiens, Margot Schoots, Ivo G. van Leeuwen, Pim J. van der Poel, Henk G. Rynja, Sybren P. Eur Urol Open Sci Prostate Cancer BACKGROUND: Considering that most men benefit diagnostically from increased sampling of index lesions, limiting systematic biopsy (SBx) to the region around the index lesion could potentially minimize overdetection while maintaining the detection of clinically significant prostate cancer (csPCa). OBJECTIVE: To evaluate the diagnostic performance of a hypothetical magnetic resonance imaging (MRI)-directed targeted-plus-perilesional biopsy approach. DESIGN, SETTING, AND PARTICIPANTS: This single-center, retrospective analysis of prospectively generated data included all biopsy-naïve men with unilateral MRI-positive lesions (Prostate Imaging Reporting and Data System category ≥3), undergoing both MRI-directed targeted biopsies and SBx. Grade group 2–5 cancers were considered csPCa. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The diagnostic performance of a targeted-plus-perilesional biopsy approach was compared with that of a targeted-plus-systematic biopsy approach. The primary outcome was the detection of csPCa. Secondary outcomes included the detection of clinically insignificant prostate cancer (ciPCa) and the number of total biopsy cores. RESULTS AND LIMITATIONS: A total of 235 men were included in the analysis; csPCa and ciPCa were detected, respectively, in 95 (40.4%) and 86 (36.6%) of these 235 men. A targeted-plus-perilesional biopsy approach would have detected 92/95 (96.8%; 95% confidence interval [CI] 91.0–99.3%) csPCa cases. At the same time, detection of systematically found ciPCa would be reduced by 11/86 (12.8%; 95% CI 6.6–21.7%). If a targeted-plus-perilesional biopsy approach would have been performed, the number of biopsy cores per patient would have been reduced significantly (a mean difference of 5.2; 95% CI 4.9–5.6, p < 0.001). CONCLUSIONS: An MRI-directed targeted-plus-perilesional biopsy approach detected almost all csPCa cases, while limiting overdiagnosis and reducing the number of biopsy cores. Prospective clinical trials are needed to substantiate the withholding of nonperilesional SBx in men with unilateral lesion(s) on MRI. PATIENT SUMMARY: Limiting systematic biopsies to the proximity of the suspicious area on magnetic resonance imaging helps detect an equivalent number of aggressive cancers and fewer indolent cancers. These findings may help patients and physicians choose the best biopsy approach. Elsevier 2022-08-02 /pmc/articles/PMC9638771/ /pubmed/36353069 http://dx.doi.org/10.1016/j.euros.2022.07.006 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Prostate Cancer
Hagens, Marinus J.
Noordzij, M. Arjen
Mazel, Jan Willem
Jager, Auke
Boellaard, Thierry N.
Tielbeek, Jeroen A.W.
Henebiens, Margot
Schoots, Ivo G.
van Leeuwen, Pim J.
van der Poel, Henk G.
Rynja, Sybren P.
An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More”
title An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More”
title_full An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More”
title_fullStr An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More”
title_full_unstemmed An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More”
title_short An Magnetic Resonance Imaging–directed Targeted-plus-perilesional Biopsy Approach for Prostate Cancer Diagnosis: “Less Is More”
title_sort magnetic resonance imaging–directed targeted-plus-perilesional biopsy approach for prostate cancer diagnosis: “less is more”
topic Prostate Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638771/
https://www.ncbi.nlm.nih.gov/pubmed/36353069
http://dx.doi.org/10.1016/j.euros.2022.07.006
work_keys_str_mv AT hagensmarinusj anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT noordzijmarjen anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT mazeljanwillem anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT jagerauke anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT boellaardthierryn anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT tielbeekjeroenaw anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT henebiensmargot anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT schootsivog anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT vanleeuwenpimj anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT vanderpoelhenkg anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT rynjasybrenp anmagneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT hagensmarinusj magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT noordzijmarjen magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT mazeljanwillem magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT jagerauke magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT boellaardthierryn magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT tielbeekjeroenaw magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT henebiensmargot magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT schootsivog magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT vanleeuwenpimj magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT vanderpoelhenkg magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore
AT rynjasybrenp magneticresonanceimagingdirectedtargetedplusperilesionalbiopsyapproachforprostatecancerdiagnosislessismore